Pfizer: Solid but Mixed Outlook Keeps Hold Rating and $26 Price Target Unchanged

Analyst Asad Haider from Goldman Sachs maintained a Hold rating on Pfizer and keeping the price target at $26.00.

Asad Haider has given his Hold rating due to a combination of factors, including solid but not transformative first-quarter execution and a balanced near-term outlook. While Pfizer outperformed expectations on revenue thanks to strong contributions from Eliquis and other key growth brands, this strength was tempered by a sharper-than-anticipated decline in the Covid-related portfolio, leaving the overall growth profile mixed.

Haider also points to a pipeline- and event-driven story, where upcoming oncology and obesity data and progress in the PCV vaccine franchise will be crucial for any meaningful re-rating of the stock. Management’s focus on organizational simplification, AI deployment, and disciplined business development within a roughly $7 billion M&A budget adds strategic clarity but does not yet justify a more aggressive stance. Accordingly, the 12-month price target is kept unchanged at $26, supporting a neutral, Hold recommendation.

According to TipRanks, Haider is a 4-star analyst with an average return of 16.0% and a 67.50% success rate. Haider covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Merck & Company, and Pfizer.

In another report released today, Morgan Stanley also maintained a Hold rating on the stock with a $28.00 price target.